UK’s NICE will cov­er $700K cost of GSK’s gene ther­a­py; Evoke shares spike on NDA plans

→ The UK’s phar­ma price watch­dog NICE has sanc­tioned cov­er­age of Glax­o­SmithK­line’s gene ther­a­py Strimvelis for “bub­ble ba­by” syn­drome, which costs about $700,000 for the once-and-done ther­a­py. About three ba­bies a year are born with ADA-SCID in the UK every year, a con­di­tion char­ac­ter­ized by a life-threat­en­ing case of im­mune de­fi­cien­cy that leaves chil­dren un­pro­tect­ed against lethal in­fec­tions. NICE says this is the first OK where it used a dif­fer­ent pric­ing guide­line for ex­tra­or­di­nar­i­ly rare dis­eases. The gene ther­a­py is avail­able in on­ly one site in Italy, where UK pa­tients will have to trav­el to for ther­a­py.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.